APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study.
Citation: Alzheimer's & Dementia. 2022 Feb 10PMID: 35142437Institution: MedStar Health Research Institute, Phoenix, ArizonaForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2022ISSN:- 1552-5260
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 35142437 | Available | 35142437 |
BACKGROUND: The apolipoprotein E (APOE) epsilon4 allele confers higher risk of neurodegeneration and Alzheimer's disease (AD), but differs by race/ethnicity. We examined this association in American Indians.
CONCLUSION: We found no evidence of neurodegenerative risk from APOE epsilon4 in American Indians. Additional studies are needed to examine potential protective features. Copyright © 2022 the Alzheimer's Association.
METHODS: The Strong Heart Study is a population-based cohort of American Indians who were 64 to 95 years of age in 2010 to 2013. APOE epsilon4 status, brain imaging, and neuropsychological testing was collected in N = 811 individuals. Summary statistics, graphics, and generalized linear regressions-adjusted for sociodemographics, clinical features, and intracranial volume with bootstrap variance estimator-compared APOE epsilon4 carriers with non-carriers.
RESULTS: APOE epsilon4 carriers comprised 22% of the population (0.7% homozygotes). Participants were mean 73 years, 67% female, and 54% had some college education. The majority were obese (>50%), hypertensive (>80%), and diabetic (>50%). Neither imaging findings nor multidomain cognitive testing showed any substantive differences between APOE epsilon4 carriers and non-carriers.
English